［1］Massagué J.TGF-beta in cancer［J］.Cell，2008，134：215-230.
[2]Fleming NI，Jorissen RN，Mouradov D，et al.SMAD2，SMAD3 and SMAD4 mutations in colorectal cancer［J］.Cancer Res，2013，73：725-735.
[3]Massagué J.TGFβ signalling in context［J］.Nat Rev Mol Cell Biol，2012，13：616-630.
[4]Massagué J.How cells read TGF-beta signals［J］.Nat Rev Mol Cell Biol，2000，1：169-178.
[5]Akhurst RJ，Hata A.Targeting the TGFβ signalling pathway in disease［J］.Nat Rev Drug Discov，2012，11：790-811.
[6]Mu Y，Gudey SK.Non-Smad signaling pathways［J］.Cell Tissue Res，2012，347：11-20.
[7]Zhang YE.Non-Smad pathways in TGF-beta signaling［J］.Cell Res，2009，19：128-139.
[8]Lingling Guo，Yongsheng Zhang，Lifeng Zhang，et al.MicroRNAs，TGF-β signaling，and the inflammatory microenvironment in cancer［J］.Tumour Biol，2016，37(1)：115-125.
[9]Lin RL，Zhao LJ.Mechanistic basis and clinical relevance of the role of transforming growth factor-β in cancer［J］.Cancer Biol Med，2015，12(4)：385-393.
[10]Bierie B，Moses HL.Gain or loss of TGF beta signaling in mammary carcinoma cells can promote metastasis［J］.Cell Cycle，2009，8：3319-3327.
[11]Perlman R，Schiemann WP，Brooks MW，et al.TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation［J］.Nat Cell Biol，2001，3：708-714.
[12]Barrack ER.TGF beta in prostate cancer：A growth inhibitor that can enhance tumorigenicity［J］.Prostate，1997，31：61-70.
[13]Bierie B，Stover DG，Abel TW，et al.Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment［J］.Cancer Res，2008，68：1809-1819.
[14]Carvalho F，Colleoni GW，Almeida MS，et al.TGFβR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma［J］.Int J Cancer，2009，125：1985-1991.
[15]Boye A，Kan H，Wu C，et al.MAPK inhibitors differently modulate TGF-beta/Smad signaling in HepG2 cells［J］.Tumour Biol，2015，10：258-264.
[16]Lin H，Huang CC，Ou YC，et al.High immunohistochemical expression of TGF-beta1 predicts a poor prognosis in cervical cancer patients who harbor enriched endoglin microvessel density［J］.Int J Gynecol Pathol，2012，31：482-489.
[17]Bellone G，Gramigni C，Vizio B，et al.Abnormal expression of Endoglin and its receptor complex (TGF-beta1 and TGF-beta receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa［J］.Int J Oncol，2010，37：1153-1165.
[18]Shio Kobayashi，Takeshi Watanabe，Ryo Suzuki，et al.TGF-β induces the differentiation of human CXCL13-producing CD4+ T cells［J］.Eur J Immunol，2016，46(2)：360-371.
[19]Zhang WJ，He ZM.TGFβ2/Snail-mediated EMT confers 5-FU resistance in human breast cancer［D］.Hunan:Central South University，2012.［张为家，贺智敏.TGFβ2经Snail介导的上皮-间质转化（EMT）在乳腺癌5-FU耐药中的作用及机制［D］.湖南：中南大学，2012.］
[20]Bai WD，Yang AG，Jia LT.MiR-200 suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer［D］.Shaanxi:Fourth Military Medical University，2015.
[21]Wu JJ，Shao CS，Wei JJ.Functional and mechanistic studies of HMGA2 in the regulation of epithelial-mesenchymal transition in ovarian cancer［D］.Shandong:Shandong University，2012.［吴晶晶，邵常顺，魏建军.HMGA2在卵巢癌上皮间质转化过程中的作用及机制研究［D］.山东:山东大学，2012.］
[22]Jia Xu，Sunil Acharya，Ozgur Sahin，et al.4-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2［J］.Cancer Cell，2015，27(2)：177-192.
[23]Gabriele Romano，Ludovica Santi，Maria Rosaria Bianco，et al.The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells［J］.Oncotarget，2016，7(16)：22077-22091.
[24]Naoki Oshimori，Daniel Oristian，Elaine Fuchs.TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma［J］.Cell，2015，160(5)：963-976.
[25]Liu RM，Desai LP.Reciprocal regulation of TGF-β and reactive oxygen species：A perverse cycle for fibrosis［J］.Redox Biol，2015，6：565-577.
[26]Diede Brunen，Stefan M Willems.TGF-β:An emerging player in drug resistance［J］.Cell Cycle，2013，12(18)：2960-2968.
[27]Huang S，Hlzel M，Knijnenburg T，et al.MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling［J］.Cell，2012，151(93)：750.
[28]Zhao HH，Chen Y.Expression of PKCα and TGF-β1 proteins in exocrine pancreatic carcinoma and their relationship［J］.Acad J Sec Mil Med Univ，2005，26(10)：1092-1094.
[29]Fayun Zhang，Wenjuan Dong，Wenfeng Zeng，et al.Naringenin prevents TGF-β1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation［J］.Breast Cancer Res，2016，18：38.
[30]Shulin Xiang，Yi Zeng，Bin Xiong，et al.Transforming growth factor beta 1 induced endothelin-1 release is peroxisome proliferator-activated receptor gamma dependent in A549 cells［J］.J Inflamm (Lond)，2016，13：19.
[31]Peter J Wermuth，Zhaodong Li，Mendoza FA,et al.Stimulation of transforming growth factor-β1-induced endothelial-to-mesenchymal transition and tissue fibrosis by endothelin-1 (ET-1)：A novel profibrotic effect of ET-1［J］.PLoS One，2016，11(9)：e0161988.
[32]Rooban B Nahomi，Mina B Pantcheva，Ram H Nagaraj，et al.αB-crystallin is essential for the TGF-β2-mediated epithelial to mesenchymal transition of lens epithelial cells［J］.Biochem J，2016，473(10)：1455-1469.
[33]Heng-Kien Au，Jui-Hung Chang，Yu-Chih Wu，et al.TGF-βI regulates cell migration through pluripotent transcription factor OCT4 in endometriosis［J］.PLoS One，2015，10(12)：e0145256.
[34]Meijuan Zou，Wei Zhu，Li Wang，et al.AEG-1/MTDH-activated autophagy enhances human malignant glioma susceptibility to TGF-β1-triggered epithelial-mesenchymal transition［J］.Oncotarget，2016，7(11)：13122-13138.
[35]Baby Periyanayaki Muthusamy，Erine H Budi，Yoko Katsuno，et al.ShcA protects against epithelial-mesenchymal transition through compartmentalized inhibition of TGF-β-induced Smad activation［J］.PLoS Biol，2015，13(12)：1002325.
[36]López-Díaz FJ，Gascard P，Balakrishnan SK，et al.Coordinate transcriptional and translational repression of p53 by TGF-β1 impairs the stress response［J］.Mol Cell，2013，50：552-564.
[37]Miller LD，Smeds J，George J，et al.An expression signature for p53 status in human breast cancer predicts mutation status，transcriptional effects，and patient survival［J］.Proc Natl Acad Sci USA，2005，102(13)：550-555.
[38]Sayan AE，Griffiths TR，Pal R，et al.SIP1 protein protects cells from DNA damage induced apoptosis and has independent prognostic value in bladder cancer［J］.Proc Natl Acad Sci USA，2009，106：14884-14889.
[39]Kirshner J，Jobling MF，Pajares MJ，et al.Inhibition of transforming growth factor-beta1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress［J］.Cancer Res，2006，66：10861-10869.
[40]Pham CG，Bubici C，Zazzeroni F，et al.Upregulation of Twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs［J］.Mol Cell Biol，2007，27(39)：20-35.
[41]Connolly EC，Freimuth J,Akhurst RJ.Complexities of TGF-β targeted cancer therapy［J］.International J Biological Sciences，2012，8(7)：964-978.
[42]Nam JS，Terabe M，Mamura M，et al.An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments［J］.Cancer Res，2008，68：3835-3843.
[43]Yang YA，Dukhanina O，Tang B，et al.Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects［J］.Clin Invest，2002，109：1607-1615.
[44]Morris JC，Tan AR,Olencki TE,et al.Phase Ⅰ study of GC1008 (Fresolimumab)：A human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma［J］.PLoS One，2014，9(3)：e90353.
[45]Hau P，Jachimczak P，Schlingensiepen R，et al.Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas：From preclinical to phase I/II studies［J］.Oligonucleotides，2007，17：201-212.
[46]Schlingensiepen KH，Jaschinski F，Lang SA，et al.Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer［J］.Cancer Sci，2011，102：1193-1200.
[47]Ehata S，Hanyu A，Fujime M，et al.Ki26894，a novel transforming growth factor-beta type I receptor kinase inhibitor，inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line［J］.Cancer Sci，2007，98：127-133.
[48]Mohammad KS，Javelaud D，Fournier PG，et al.TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases［J］.Cancer Res，2011，71：175-184.
[49]Zhao BM，Hoffmann FM.Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA［J］.Mol Biol Cell，2006，17：3819-3831.
[50]Wang N，Yang XS.Correlation with promoter hypermethylation of TGFβⅠ and chemoresistance in human ovarian cancer［D］.Shandong：Shandong University，2012.
[51]Puteri Baharuddin，Nazila Satar.Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines［J］.Oncology Reports，2016，35：13-25.
[52]Wang W，Chen WQ.Roles of p15 on MDR of hepatoma and the underlying mechanisms［D］.Chongqing：Chongqing University，2009.［王微，陈伟庆.p15因子与肝癌多药耐药的相关性及作用机制的研究［D］.重庆：重庆医科大学，2009.］
[53]Yin Q，Liu S，Dong A,et al.Targeting transforming frowth factor-beta1 (TGF-β1) inhibits tumorigenesis of anaplastic thyroid carcinoma cells through ERK1/2-NF-κB-PUMA signaling［J］.Med Sci Monit，2016，22：2267-2277.
[54]Han Xiao，Jianshu Zhang，Zhonghe Xu，et al.Metformin is a novel suppressor for transforming growth factor (TGF)-β1［J］.Sci Rep，2016，6：28597.
[55]Li NS，Zou JR，Lin H，et al.LKB1/AMPK inhibits TGF-β1 production and the TGF-β signaling pathway in breast cancer cells［J］.Tumour Biol，2016，37(6)：8249-8258.